Natera, Inc.
NTRA
株式のランク
#410
Natera, Inc. is a diagnostics company focused on developing and commercializing... Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
株価
$408.82
時価総額
$58.93B
変化（1日）
2.35%
変化（1年）
116.76%
国
US
取引 Natera, Inc. (NTRA)
カテゴリー
Healthcare
Natera, Inc.（NTRA）の利益
Jun 2026 時点の利益 TTM: $-252.70M
Natera, Inc. の最新の財務報告によると、同社の現在の利益は $-252.70M です。2023 年には $-434.53M の利益を上げ、これは 2022 年の利益 $-546.82M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Natera, Inc. の利益の推移（2012 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-252.70M | 33.19% |
| 2024 | $-189.73M | -56.34% |
| 2023 | $-434.53M | -20.54% |
| 2022 | $-546.82M | 16.07% |
| 2021 | $-471.10M | 105.14% |
| 2020 | $-229.65M | 86.96% |
| 2019 | $-122.83M | -3.92% |
| 2018 | $-127.83M | -5.91% |
| 2017 | $-135.86M | 42.08% |
| 2016 | $-95.62M | 36.07% |
| 2015 | $-70.28M | 1,264.03% |
| 2014 | $-5.15M | -86.12% |
| 2013 | $-37.11M | -51.28% |
| 2012 | $-76.17M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $7.61B | -3,111.07% |
US
|
|
| $4.76B | -1,984.44% |
US
|
|
| - | - |
CN
|
|
| $1.66B | -756.11% |
US
|
|
| $1.61B | -736.72% |
US
|
